CASI Pharmaceuticals Inc. (CASI)

Oncology Corporate Profile

Stock Performance

1.3800
-0.0500

HQ Location

9620 Medical Center Drive, Suite 300
Rockville, MD 20850

Company Description

CASI is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China

Website: http://www.casipharmaceuticals.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ENMD-2076aurora A/angiogenic kinase inhibitorBreast cancerII
ENMD-2076aurora A/angiogenic kinase inhibitorfibrolamellar carcinomaII

View additional information on product candidates here »

Source


http://www.casipharmaceuticals.com

Recent News Headlines

CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting

3/28/2017 11:00 am

[PR Newswire] - ROCKVILLE, Md., March 28, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...

CASI Pharmaceuticals' Import Drug Registration Application For EVOMELA® Accepted For Review By CFDA

12/5/2016 12:00 pm

[PR Newswire] - ROCKVILLE, Md., Dec. 5, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announced today that China's Food and Drug Administration (CFDA) has accepted for review the Company's import drug registration application for EVOMELA® (melphalan) for Injection. CASI's China rights to EVOMELA (melphalan) for Injection was previously licensed from its partner Spectrum Pharmaceuticals, Inc. along with two other commercial-stage Spectrum drugs, MARQIBO® and ZEVALIN®. EVOMELA received U.S. FDA approval earlier this year for multiple myeloma patients as a high-dose conditioning treatment prior to autologous stem cell transplantation (ASCT) and as palliative treatment for patients who are not candidates for oral therapy. It was launched in the U.S. this year by Spectrum.

CASI Pharmaceuticals Reports Third Quarter 2016 Financial Results

11/14/2016 12:01 pm

[at noodls] - ROCKVILLE, Md., Nov. 14, 2016 /PRNewswire/- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...

CASI Pharmaceuticals Reports Third Quarter 2016 Financial Results

11/14/2016 12:00 pm

[PR Newswire] - ROCKVILLE, Md., Nov. 14, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...

CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma

8/16/2016 01:04 pm

[at noodls] - ROCKVILLE, Md., Aug. 16, 2016 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today announced that ...

CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma

8/16/2016 11:00 am

[PR Newswire] - ROCKVILLE, Md., Aug. 16, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today announced that its Phase 2 trial of ENMD-2076 in fibrolamellar carcinoma (FLC) has met its Stage 1 endpoint of objective response for non-futility based on the pre-specified interim analysis criteria and will advance to Stage 2 development. Rong Chen, M.D., CASI's Chief Medical Officer, commented, "The trial is to evaluate safety and efficacy of ENMD-2076 as a single agent in a total of 29 locally-advanced or metastatic FLC patients. Having met the Stage 1 endpoint, we will now advance the trial to Stage 2 development.

CASI Pharmaceuticals Reports Second Quarter 2016 Financial Results

8/15/2016 02:04 pm

[at noodls] - ROCKVILLE, Md., Aug. 15, 2016 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today reported financial ...

CASI Pharmaceuticals Reports Second Quarter 2016 Financial Results

8/15/2016 11:00 am

[PR Newswire] - ROCKVILLE, Md., Aug. 15, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...

Boston Biomedical Announces First Orphan Drug Designation for Napabucasin in Gastric/GEJ Cancer

6/24/2016 12:34 pm

(Boston Biomedical) June 23, 2016 - Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced that its lead investigational compound, napabucasin, has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the treatment of gastric cancer, including gastroesophageal junction (GEJ) cancer.

CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076

6/13/2016 03:02 am

[at noodls] - Antitumor Activity, Safety and Predictive Biomarker Results to be Presented ROCKVILLE, Md., June 1, 2016 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics ...

Genomic Health Announces Multiple Oncotype DX(R) Presentations at ASCO 2016 Showcasing Industry-leading Commitment to Bringing Precision Medicine to Cancer Patients

6/5/2016 06:26 pm

(The Business Journals) June 5, 2016 - Four new analyses of SEER registry provide additional evidence that Oncotype DX accurately predicts patient outcomes in node-negative and node-positive breast cancer and reinforce its value in older women; oral presentation highlights positive impact Oncotype DX has on decision making process, including in node-positive disease.

CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Cle

6/1/2016 11:01 am

[at noodls] - Antitumor Activity, Safety and Predictive Biomarker Results to be Presented ROCKVILLE, Md., June 1, 2016 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics ...

CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC)

6/1/2016 11:00 am

[PR Newswire] - ROCKVILLE, Md., June 1, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...

CASI Pharmaceuticals Reports First Quarter 2016 Financial Results

5/13/2016 11:01 am

[at noodls] - ROCKVILLE, Md., May 13, 2016 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today reported ...